BVD’s pipeline comprises Ulixertinib (BVD-523), a small-molecule ERK1/2 kinase inhibitor in phase 2 trials for cancers with MAPK pathway mutations; Clostridium novyi-NT (CNV-NT), a tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback